“No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices,” Attorney General Eric T. Schneiderman said. “If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable. Allergy sufferers have enough concerns to worry about—the availability of life-saving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation.”

NEW YORK – Today, Attorney General Eric T. Schneiderman announced his office has commenced an investigation into Mylan Pharmaceuticals Inc, the maker of EpiPens. A preliminary review by the Office of the Attorney General revealed that Mylan Pharmaceuticals may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems. Mylan’s EpiPen is the predominant epinephrine autoinjector—a device and drug used in cases where an individual suffers a severe allergic reaction, which could otherwise lead to death—in the U.S. market.

NOTICE: This is an archived press release. Information contained on this page may be outdated. Please refer to our latest press releases for up-to-date information.

Select a Language Below / Seleccione el Idioma Abajo

Disclaimer

This Google™ translation feature is provided for informational purposes only.

The Office of Attorney General's website is provided in English. However, the "Google Translate" option may assist you in reading it in other languages.

Google Translate cannot translate all types of documents, and it may not give you an exact translation all the time. Anyone relying on information obtained from Google Translate does so at his or her own risk.

The Office of Attorney General does not make any promises, assurances, or guarantees as to the accuracy of the translations provided. The State of New York, its officers, employees, and/or agents shall not be liable for damages or losses of any kind arising out of, or in connection with, the use or performance of such information, including but not limited to, damages or losses caused by reliance upon the accuracy of any such information, or damages incurred from the viewing, distributing, or copying of such materials.

A copy of this disclaimer can also be found on our Disclaimer page.

Close this box or use the [ X ]